Business Wire · JNJ · November 1, 2026

Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

Get the app for more

Explore stock news, insights and company research.